首页> 外文期刊>Tissue engineering, Part A >The nitric oxide donor S-nitrosoglutathione reduces apoptotic primary liver cell loss in a three-dimensional perfusion bioreactor culture model developed for liver support.
【24h】

The nitric oxide donor S-nitrosoglutathione reduces apoptotic primary liver cell loss in a three-dimensional perfusion bioreactor culture model developed for liver support.

机译:一氧化氮供体S-亚硝基谷胱甘肽在为肝脏支持而开发的三维灌注生物反应器培养模型中减少了凋亡性原代肝细胞的损失。

获取原文
获取原文并翻译 | 示例
           

摘要

INTRODUCTION: Artificial extracorporeal support for hepatic failure has met with limited clinical success. In hepatocytes, nitric oxide (NO) functions as an antiapoptotic modulator in response to a variety of stresses. We hypothesized that NO administration would yield improved viability and hepatocellular restructuring in a four-compartment, hollow fiber-based bioreactor with integral oxygenation for dynamic three-dimensional perfusion of hepatic cells in bioartificial liver support systems. METHODS: Isolated adult rat liver cells were placed in culture medium alone (control) or medium supplemented with various concentrations of an NO donor (S-nitrosoglutathione [GSNO]) in the bioreactors. Media samples were obtained from the cell perfusion circuit to monitor cellular response. After 24 and 72 h, histology biopsies were taken to investigate spontaneous restructuring of the cells. Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay was performed to quantify apoptotic nuclei. RESULTS: Control bioreactors exhibited 47.9 +/- 2.9% (mean +/- standard error of the mean) apoptotic nuclei. In contrast, NO-treated bioreactors exhibited a biphasic response. Fewer apoptotic nuclei were seen in the 200 and 500 microM GSNO groups (14.4 +/- 0.4%). No effect was observed in the 10 microM GSNO group (47.3%), and increased TUNEL staining was observed in the 1000 microM GSNO group (82.6%). Media lactate dehydrogenase levels were lower in bioreactor groups treated with 200 or 500 microM GSNO (310 +/- 38 IU/L) compared with the control group (919 +/- 188 IU/L; p < 0.05). Protein synthesis was not affected, as measured by albumin levels in the media (115 +/- 19 microg/day/cell inoculum in GSNO-treated bioreactors at 24 h vs. 110 +/- 13 in controls; p = 0.851). Histologically, all of the bioreactor groups exhibited liver cell aggregates with some attached to the bioreactor capillaries. Increased numbers of cells in the aggregates and superior spontaneous restructuring of the cells were seen at 24 and 72 h in the bioreactor groups treated with either 200 or 500 microM GSNO compared with the control groups. CONCLUSION: Addition of an NO donor reduces adult rat liver cell apoptosis during the initial 24 h after cell inoculation within a three-dimensional perfusion bioreactor system for liver support and promotes liver cell aggregation and spontaneous restructuring of the cells at 24 and 72 h. GSNO-treated bioreactors remain metabolically active and show significantly lower levels of cellular injury as compared with controls. Further studies will be required to evaluate the impact of NO treatment of liver support bioreactors for clinical studies.
机译:简介:人工肝外支持对肝衰竭的临床成功率有限。在肝细胞中,一氧化氮(NO)响应多种应激而起抗凋亡调节剂的作用。我们假设,NO给药将在具有整体氧合作用的四室,中空纤维基生物反应器中产生改善的生存力和肝细胞重构,以在生物人工肝支持系统中动态进行肝细胞的三维灌注。方法:将分离的成年大鼠肝细胞置于单独的培养基(对照)或补充了生物反应器中各种浓度的NO供体(S-亚硝基谷胱甘肽[GSNO])的培养基中。从细胞灌注回路获得培养基样品以监测细胞反应。 24和72小时后,进行组织学活检以研究细胞的自发重组。进行末端脱氧核苷酸转移酶dUTP缺口末端标记(TUNEL)测定以量化凋亡核。结果:对照生物反应器显示出47.9 +/- 2.9%(平均值的平均+/-标准误)凋亡细胞核。相反,NO处理的生物反应器表现出双相反应。在200和500 microM GSNO组中观察到较少的凋亡核(14.4 +/- 0.4%)。在10 microM GSNO组(47.3%)中未观察到效果,而在1000 microM GSNO组(82.6%)中未观察到TUNEL染色增加。与对照组相比,用200或500 microM GSNO处理的生物反应器组中的培养基乳酸脱氢酶水平较低(310 +/- 38 IU / L)(919 +/- 188 IU / L; p <0.05)。如通过培养基中的白蛋白水平所测量的(在GSNO处理的生物反应器中,在24 h时为115 +/- 19微克/天/细胞接种物,而在对照组中为110 +/- 13; p = 0.851),则蛋白质合成不受影响。组织学上,所有生物反应器组均表现出肝细胞聚集体,其中一些附着于生物反应器毛细管上。与对照组相比,在用200或500 microM GSNO处理的生物反应器组中,在24和72 h观察到聚集物中细胞数量的增加和卓越的自发重组。结论:添加NO供体可减少成年大鼠肝脏细胞在接种后24小时内在支持肝脏的三维灌注生物反应器系统中的凋亡,并促进肝细胞聚集和在24和72小时时细胞的自发重组。与对照组相比,经GSNO处理的生物反应器仍具有代谢活性,并显示出明显更低的细胞损伤水平。需要进一步的研究来评估NO治疗对肝脏支持生物反应器的影响,以进行临床研究。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号